WallStreetZenWallStreetZen

NASDAQ: SSKN
Strata Skin Sciences Inc Stock

$3.14+0.12 (+3.97%)
Updated Jul 15, 2024
SSKN Price
$3.14
Fair Value Price
-$1.15
Market Cap
$11.01M
52 Week Low
$2.62
52 Week High
$10.80
P/E
-0.95x
P/B
1.17x
P/S
0.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.55M
Earnings
-$11.36M
Gross Margin
52.7%
Operating Margin
-29.43%
Profit Margin
-34.9%
Debt to Equity
3.25
Operating Cash Flow
-$120k
Beta
0.55
Next Earnings
Aug 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SSKN Overview

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SSKN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SSKN ($3.14) is overvalued by 373.11% relative to our estimate of its Fair Value price of -$1.15 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SSKN ($3.14) is not significantly undervalued (373.11%) relative to our estimate of its Fair Value price of -$1.15 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SSKN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SSKN due diligence checks available for Premium users.

Be the first to know about important SSKN news, forecast changes, insider trades & much more!

SSKN News

Valuation

SSKN fair value

Fair Value of SSKN stock based on Discounted Cash Flow (DCF)
Price
$3.14
Fair Value
-$1.15
Undervalued by
373.11%
SSKN ($3.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SSKN ($3.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SSKN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SSKN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.95x
Industry
30.11x
Market
31.91x

SSKN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
3.85x
SSKN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SSKN's financial health

Profit margin

Revenue
$6.8M
Net Income
-$3.4M
Profit Margin
-49.9%
SSKN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SSKN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$40.0M
Liabilities
$30.6M
Debt to equity
3.25
SSKN's short-term assets ($13.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSKN's long-term liabilities ($18.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSKN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SSKN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$804.0k
Investing
-$725.0k
Financing
-$18.0k
SSKN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SSKN vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
SSKN$11.01M+3.97%-0.95x1.17x
NXL$10.63M+0.70%-2.17x4.57x
VVOS$8.91M-1.78%-0.25x15.30x
PAVM$8.87M+9.43%-0.10x-0.13x
NUVO$14.10M-3.96%-0.57x-0.21x

Strata Skin Sciences Stock FAQ

What is Strata Skin Sciences's quote symbol?

(NASDAQ: SSKN) Strata Skin Sciences trades on the NASDAQ under the ticker symbol SSKN. Strata Skin Sciences stock quotes can also be displayed as NASDAQ: SSKN.

If you're new to stock investing, here's how to buy Strata Skin Sciences stock.

What is the 52 week high and low for Strata Skin Sciences (NASDAQ: SSKN)?

(NASDAQ: SSKN) Strata Skin Sciences's 52-week high was $10.80, and its 52-week low was $2.62. It is currently -70.93% from its 52-week high and 19.85% from its 52-week low.

How much is Strata Skin Sciences stock worth today?

(NASDAQ: SSKN) Strata Skin Sciences currently has 3,506,092 outstanding shares. With Strata Skin Sciences stock trading at $3.14 per share, the total value of Strata Skin Sciences stock (market capitalization) is $11.01M.

Strata Skin Sciences stock was originally listed at a price of $2,560.00 in Nov 3, 2005. If you had invested in Strata Skin Sciences stock at $2,560.00, your return over the last 18 years would have been -99.88%, for an annualized return of -31.09% (not including any dividends or dividend reinvestments).

How much is Strata Skin Sciences's stock price per share?

(NASDAQ: SSKN) Strata Skin Sciences stock price per share is $3.14 today (as of Jul 15, 2024).

What is Strata Skin Sciences's Market Cap?

(NASDAQ: SSKN) Strata Skin Sciences's market cap is $11.01M, as of Jul 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Strata Skin Sciences's market cap is calculated by multiplying SSKN's current stock price of $3.14 by SSKN's total outstanding shares of 3,506,092.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.